Clinical Trial Update: Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial [Phase 4]

View source ↗

Summary

A Phase 4 trial (ERIN) evaluating erythropoietin for prevention of contrast-induced nephropathy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Nephropathy

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Contrast Induced Nephropathy | Phase 4 | Status: TERMINATED